查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年美國和歐洲細胞和基因治療製造服務市場預測 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）、最終用戶和國家進行區域分析
市場調查報告書
商品編碼
1347187

到 2030 年美國和歐洲細胞和基因治療製造服務市場預測 - 按類型、適應症（癌症、骨科等）、應用（臨床製造和商業製造）、最終用戶和國家進行區域分析

US and Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User, and Country
出版日期: | 出版商: The Insight Partners | 英文 147 Pages | 訂單完成後即時交付

價格

2022年，美國和歐洲的細胞和基因治療製造服務市場價值為47.735億美元，預計到2030年將達到168.691億美元；預計2022年至2030年年複合成長率為17.1%。

細胞和基因療法批准數量的增加以及外包細胞和基因療法製造服務的日益普及是影響美國和歐洲細胞和基因療法製造服務市場規模成長的主要因素。然而，細胞和基因治療製造服務的高初始成本阻礙了美國和歐洲細胞和基因治療製造服務市場的成長。

細胞和基因治療（CGT）項目正在從研發快速推進到臨床試驗和商業批准。建立穩健、可重複且永續的流程有助於加速開發，避免與製造轉移相關的延誤。此外，細胞和基因療法包括下一代生命增強和治療療法。隨著療法獲得新的批准，對細胞和基因療法製造服務領域熟練專業人員的需求將會上升。

外包細胞和基因治療製造越來越受歡迎

細胞和基因療法的製造是一個複雜的過程，這使得正確執行和監督操作至關重要。細胞和基因治療製造商了解生物和工藝工程的合格人員數量有限。此外，對於經驗豐富的團隊來說，使用手動和開放製造方法來管理首次臨床試驗的嘗試，然後構建更適合商業的流程可能會很棘手。因此，這些企業選擇與契約開發和製造組織（CDMO）合作來加速其臨床研究和商業化進程。 CDMO 以契約形式向細胞和基因治療公司提供產品開發、製造、臨床試驗支持和商業化服務。與 CDMO 合作可以幫助細胞和基因治療製造商實現可擴展性、加快上市速度、無需管理成本即可獲得技術專業知識以及成本效率。

2020年1月，Deerfield Management Company和MLP Ventures的發現實驗室在美國賓夕法尼亞州建立了突破性藥物中心。這個新的 CDMO 設施將佔據 Discovery Labs 園區 40% 以上的面積。在該空間中，CDMO 將安裝 10 個質粒套件； 20 個病毒載體套件； 36 個通用細胞處理套件；以及 20 個現行良好生產規範 (cGMP) 測試、工藝開發和細胞庫套件。 Deerfield Management Company 和 Discovery Labs 已投資 11 億美元建設技術開發設施，以支持細胞和基因療法的生產。此外，2020年3月，Fujifilm Cellular Dynamics（FCDI）投資2100萬美元建設符合cGMP的生產設施，該設施將用於製造FCDI使用誘導多能幹細胞（iPSC）的再生醫學療法的管道並提供CDMO服務用於生產iPSC 和iPSC 衍生的分化細胞。 2022年4月，ThermoGenesis在美國加利福尼亞州建立了CDMO設施，利用其在T細胞受體（TCR）、嵌合抗原受體-T細胞（CAR-T細胞）、腫瘤等領域的專業知識，為細胞和基因治療製造商提供CDMO服務。 -浸潤白細胞（TIL）、iPSC、自然殺傷細胞（NK）和間充質幹細胞（MSC）製造。

事實證明，將細胞和基因治療製造外包給 CDMO 對於製造商來說具有成本效益。此外，他們還可以獲得 CDMO 技術先進的基礎設施和專業知識。 CDMO 採用適當的、映射的流程來製造細胞和基因療法。因此，越來越傾向於將不斷成長的細胞和基因治療製造外包給 CDMO，推動了美國和歐洲細胞和基因治療製造服務市場的成長。

細分分析

基於最終用戶的見解

根據最終用戶，市場分為製藥和生物技術公司以及契約研究組織（CRO）。製藥和生物技術公司細分市場到 2022 年將佔據更大的市場佔有率，預計該細分市場在預測期內的市場年複合成長率將更高。美國主要製藥和生物技術公司致力於提供用於治療急性和罕見疾病的 CGT，這些疾病對傳統方法沒有反應，其中包括 ElevateBio 和 Discovery Labs。這些公司致力於創建藥品契約開發和製造組織 (CDMO) 的全新分支。他們將通過投資資本利得稅相互競爭，並與少數大型服務公司競爭。上述因素將產生有影響力的細分市場成長，從而主導 2022-2030 年美國和歐洲細胞和基因治療製造服務市場的成長。

適應症見解

根據跡象，美國和歐洲的細胞和基因治療製造服務市場分為癌症、骨科和其他。到 2022 年，癌症細分市場佔據最大市場佔有率，預計該細分市場在預測期內將以最高年複合成長率成長。

類型洞察

根據類型，細胞和基因治療製造服務市場分為細胞治療和基因治療。細胞療法分為自體細胞療法和同種異體細胞療法。此外，基因治療分為病毒載體和非病毒載體。細胞療法通過恢復或改變某些細胞群或提供細胞在體內進行治療來幫助治療紊亂和疾病。細胞療法在引入患者之前在體外形成或修飾細胞。細胞可以來自患者（自體細胞）或供體（同種異體細胞）。細胞療法領域的成長歸因於進入市場的產品數量不斷增加、細胞療法在治療自身免疫性疾病、癌症和傳染病方面的潛在應用以及大量正在進行的臨床試驗。超過 360 項專注於 CAR-T 細胞療法和其他細胞療法的臨床試驗正在研究中，以解釋這些療法治療各種疾病適應症的潛力。因此，預計未來幾年對先進治療製造服務的需求將會增加。

在準備美國和歐洲細胞和基因治療製造服務市場報告時提到的一些主要一手和二手來源是美國國立衛生研究院基金會、國家衛生服務機構以及藥品和保健產品監管局。

目錄

第 1 章：簡介

  • 研究範圍
  • Insight Partners 研究報告指南
  • 市場區隔
    • 美國和歐洲細胞和基因治療製造服務市場 - 按類型
    • 美國和歐洲細胞和基因治療製造服務市場 - 按適應症分類
    • 美國和歐洲細胞和基因治療製造服務市場 - 按應用
    • 美國和歐洲細胞和基因治療製造服務市場 - 按最終用戶
    • 美國和歐洲細胞和基因治療製造服務市場 - 按國家和地區分類

第 2 章：美國和歐洲細胞和基因治療製造服務市場 - 要點

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：美國和歐洲細胞和基因治療製造服務市場 - 市場格局

  • 概述
  • PEST分析
    • 美國PEST分析
    • 歐洲PEST分析
  • 專家意見

第 5 章：美國和歐洲細胞和基因治療製造服務市場 - 主要市場動態

  • 市場促進因素
    • 細胞和基因療法批准數量的增加
    • 外包細胞和基因治療製造越來越受歡迎
  • 市場限制
    • 細胞和基因療法製造成本高昂
  • 市場機會
    • 公司的戰略舉措
  • 未來的趨勢
    • 細胞和基因治療製造服務的自動化
  • 影響分析

第 6 章：美國和歐洲細胞和基因治療製造服務市場 - 國家和地區分析

  • 美國和歐洲細胞和基因治療製造服務市場收入預測與分析
  • 關鍵參與者的市場定位

第 7 章：美國和歐洲細胞和基因治療製造服務市場 - 收入和 2030 年預測 - 按類型

  • 概述
  • 美國和歐洲細胞和基因治療製造服務市場收入佔有率，按類型 2022 年和 2030 年 (%)
  • 細胞療法
  • 基因治療

第 8 章：美國和歐洲細胞和基因治療製造服務市場分析和 2030 年預測 - 按指標

  • 概述
  • 美國和歐洲細胞和基因治療製造服務市場，按適應症分類 2022 年和 2030 年 (%)
  • 癌症
  • 骨科
  • 其他

第 9 章：美國和歐洲細胞和基因治療製造服務市場 - 收入和 2030 年預測 -按應用

  • 概述
  • 2022 年和 2030 年美國和歐洲細胞和基因治療製造服務市場收入佔有率（按應用分類）
  • 臨床製造
  • 商業製造

第 10 章：美國和歐洲細胞和基因治療製造服務市場 - 收入和 2030 年預測 - 按最終用戶

  • 概述
  • 2022 年和 2030 年美國和歐洲細胞和基因治療製造服務市場收入佔有率（按最終用戶分類）（%）
  • 製藥和生物技術公司
  • 契約研究組織 (CRO)

第 11 章：美國和歐洲細胞和基因治療製造服務市場 - 收入和 2030 年預測 - 國家和地區分析

    • 概述
      • 美國：2020-2030 年美國和歐洲細胞和基因治療製造服務市場（按類型）
      • 美國：美國和歐洲細胞和基因治療製造服務市場，按適應症分類，2020-2030 年
      • 美國：2020-2030 年美國和歐洲細胞和基因治療製造服務市場（按應用）
      • 美國：美國和歐洲細胞和基因治療製造服務市場，按最終用戶分類，2020-2030 年
  • 歐洲：美國和歐洲細胞和基因治療製造服務市場
    • 概述
    • 歐洲：2020-2030 年美國和歐洲細胞和基因治療製造服務市場（按類型）
      • 歐洲：美國和歐洲細胞和基因治療製造服務市場，按 Cell Therapy 分類，2020-2030 年
      • 歐洲：美國和歐洲細胞和基因治療製造服務市場，按 Gene Therapy 分類，2020-2030 年
    • 歐洲：美國和歐洲細胞和基因治療製造服務市場，按適應症分類，2020-2030 年
    • 歐洲：2020-2030 年美國和歐洲細胞和基因治療製造服務市場（按應用）
    • 歐洲：美國和歐洲細胞和基因治療製造服務市場，按最終用戶分類，2020-2030 年
    • 歐洲：美國和歐洲細胞和基因治療製造服務市場，按國家/地區分類，2022 年和 2030 年（%）

第 12 章：美國和歐洲細胞和基因治療製造服務市場 - 行業格局

  • 概述
  • 美國和歐洲細胞和基因治療製造服務市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd?
  • Catalent Inc
  • Takara Bio Inc
  • Nikon Corp
  • FUJIFILM Holdings Corp
  • National Resilience Inc
  • Oxford BioMedica Plc

第 14 章：附錄

  • 關於 Insight Partners
  • 專業術語
Product Code: TIPRE00029984

The US and Europe cell and gene therapy manufacturing services market was valued at US$ 4,773.5 million in 2022 and is projected to reach US$ 16,869.1 million by 2030; it is estimated to register a CAGR of 17.1% from 2022 to 2030.

An increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing services are among the major contributing factors influencing the growth of US and Europe cell and gene therapy manufacturing services market size. However, high initial cost of cell and gene therapy manufacturing services hinders the growth of the US and Europe cell and gene therapy manufacturing services market.

Cell and gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing a robust, repeatable, and sustainable process help to accelerate the development, avoiding manufacturing transfer-related delays. Additionally, cell and gene therapy comprises the next generation of life-enhancing and curative therapies. With therapies experiencing new approvals, the demand for skilled professionals in cell and gene therapy manufacturing services will rise.

Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing

Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers.

In January 2020, Deerfield Management Company and The Discovery Labs of MLP Ventures established the Center for Breakthrough Medicines in Pennsylvania, US. This new CDMO facility would occupy more than 40% of the campus created by The Discovery Labs. In that space, the CDMO would install 10 plasmid suites; 20 viral vector suites; 36 universal cell processing suites; and 20 current good manufacturing practice (cGMP) testing, process development, and cell banking suites. Deerfield Management Company and The Discovery Labs have invested US$ 1.1 billion to raise a technologically developed facility to support the manufacturing of cell and gene therapies. Further, in March 2020, Fujifilm Cellular Dynamics (FCDI) invested US$ 21 million in the cGMP-compliant production facility, which would be used for manufacturing FCDI's pipeline of regenerative medicine therapies using induced pluripotent stem cells (iPSCs) and to provide CDMO services for production of iPSCs and iPSC-derived differentiated cells. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing.

Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Moreover, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing cell and gene therapies. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the US and Europe cell and gene therapy manufacturing services market growth.

Segmental Analysis

End User-Based Insights

Based on end user, the market is segmented into pharmaceutical and biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment held a larger share of the market in 2022 and the same segment is anticipated to register a higher CAGR in the market during the forecast period. Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs. The aforementioned factors will be responsible for influential segmental growth thereby dominating the US and Europe cell and gene therapy manufacturing services market growth during 2022-2030.

Indication Insights

Based on indication, the US and Europe cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period.

Type Insights

Based on type, the cell and gene therapy manufacturing services market is segmented cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. Therefore, the demand for advanced therapy manufacturing services is anticipated to increase in the coming years.

A few of the major primary and secondary sources referred to while preparing the report on the US and Europe cell and gene therapy manufacturing services market are the Foundation for the National Institutes of Health, National Health Services, and Medicines and Healthcare Products Regulatory Agency.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US and Europe cell and gene therapy manufacturing services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US and Europe cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the US and Europe cell and gene therapy manufacturing services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Type
    • 1.3.2 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Indication
    • 1.3.3 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Application
    • 1.3.4 US and Europe Cell and Gene Therapy Manufacturing Services Market - by End User
    • 1.3.5 US and Europe Cell and Gene Therapy Manufacturing Services Market - by Country & Region

2. US and Europe Cell and Gene Therapy Manufacturing Services Market - Key Takeaways

3. Research Methodology

  • 3.2 Coverage
  • 3.3 Secondary Research
  • 3.4 Primary Research

4. US and Europe Cell and Gene Therapy Manufacturing Services Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US PEST Analysis
    • 4.2.2 Europe PEST Analysis
  • 4.3 Expert's Opinion

5. US and Europe Cell and Gene Therapy Manufacturing Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.5 Impact Analysis

6. US and Europe Cell and Gene Therapy Manufacturing Services Market - Country & Regional Analysis

  • 6.1 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • 7.3 Cell Therapy
    • 7.3.1 Overview
    • 7.3.2 Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.1 Autologous
        • 7.3.2.1.1 Overview
        • 7.3.2.1.2 Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.2 Allogenic
        • 7.3.2.2.1 Overview
        • 7.3.2.2.2 Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Viral Vector
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.2 Non-Viral Vector
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. US and Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

  • 8.1 Overview
  • 8.2 US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • 8.3 Cancer
    • 8.3.1 Overview
    • 8.3.2 Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Orthopedics
    • 8.4.1 Overview
    • 8.4.2 Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

  • 9.1 Overview
  • 9.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • 9.4 Clinical Manufacturing
    • 9.4.1 Overview
    • 9.4.2 Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Commercial Manufacturing
    • 9.5.1 Overview
    • 9.5.2 Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

  • 10.1 Overview
  • 10.2 US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 10.4 Pharmaceutical and Biotechnology Companies
    • 10.4.1 Overview
    • 10.4.2 Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Contract Research Organizations (CROs)
    • 10.5.1 Overview
    • 10.5.2 Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country & Regional Analysis

  • 11.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.1.1 Overview
    • 11.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 11.1.2.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.1.1 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.2.1.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 11.1.2.2 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 11.1.2.3 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 11.1.2.4 US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market
    • 11.2.1 Overview
    • 11.2.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.2.3 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.2.3.1 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.2.3.2 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.2.4 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.2.5 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.2.6 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.2.7 Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
      • 11.2.7.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.1 Overview
        • 11.2.7.1.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.3 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.1.3.1 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.3.2 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.4 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.1.5 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.1.6 Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.1 Overview
        • 11.2.7.2.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.3 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.2.3.1 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.3.2 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.4 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.2.5 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.2.6 UK: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.1 Overview
        • 11.2.7.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.3 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.3.3.1 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.3.2 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.4 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.3.5 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.3.6 France: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.1 Overview
        • 11.2.7.4.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.3 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.4.3.1 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.3.2 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.4 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.4.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.4.6 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.1 Overview
        • 11.2.7.5.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.3 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.5.3.1 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.3.2 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.4 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.5.5 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.5.6 Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.1 Overview
        • 11.2.7.6.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.6.3.1 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.3.2 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.6.5 Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.6.6 Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. US and Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Thermo Fisher Scientific Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck KGaA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Charles River Laboratories International Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Lonza Group AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi AppTec Co Ltd?
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Takara Bio Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Nikon Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 FUJIFILM Holdings Corp
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 National Resilience Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Oxford BioMedica Plc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 2. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. US: US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Germany US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. France US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 47. Italy US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Rest of Europe US and Europe Cell and Gene Therapy Manufacturing Services Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Recent Organic Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Table 50. Recent Inorganic Growth Strategies in the US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Table 51. Glossary of Terms

List Of Figures

  • Figure 1. US and Europe Cell and Gene Therapy Manufacturing Services Market Segmentation
  • Figure 2. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Region
  • Figure 3. US and Europe Cell and Gene Therapy Manufacturing Services Market Overview
  • Figure 4. Cell Therapy Segment Held Largest Share of Type Segment in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Figure 5. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country & Region (US$ Million)
  • Figure 6. US and Europe Cell and Gene Therapy Manufacturing Services Market - Leading Country Markets (US$ Million)
  • Figure 7. US and Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape
  • Figure 8. US: PEST Analysis
  • Figure 9. Europe: PEST Analysis
  • Figure 10. Experts' Opinion
  • Figure 11. US and Europe Cell and Gene Therapy Manufacturing Services Market: Key Industry Dynamics
  • Figure 12. US and Europe Cell and Gene Therapy Manufacturing Services Market: Impact Analysis of Drivers and Restraints
  • Figure 13. US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue Forecast and Analysis - 2021-2030
  • Figure 14. Market Positioning of Key Players in US and Europe Cell and Gene Therapy Manufacturing Services Market
  • Figure 15. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 16. Cell Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Autologous: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Allogenic: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Gene Therapy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Non-Viral Vector: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. US and Europe Cell and Gene Therapy Manufacturing Services Market, by Application 2022 & 2030 (%)
  • Figure 23. Cancer: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Orthopedics: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Others: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 27. Clinical Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Commercial Manufacturing: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. US and Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 30. Pharmaceutical & Biotechnology Companies: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Contract Research Organizations (CROs): US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. United States: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 33. US: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 35. Europe US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
  • Figure 37. Germany: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 38. UK: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 39. France: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Italy: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 41. Spain: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 42. Rest of Europe: US and Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 43. Growth Strategies in US and Europe Cell and Gene Therapy Manufacturing Services Market